Compare BGS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGS | LXEO |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.1M | 348.7M |
| IPO Year | 2004 | 2023 |
| Metric | BGS | LXEO |
|---|---|---|
| Price | $2.93 | $4.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $4.90 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 1.9M | 645.2K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 14.34% | N/A |
| EPS Growth | ★ 83.02 | 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,828,687,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.87 | $3.99 |
| 52 Week High | $6.38 | $10.99 |
| Indicator | BGS | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 26.91 | 33.74 |
| Support Level | N/A | $4.01 |
| Resistance Level | $3.75 | $5.38 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 9.42 | 5.10 |
B&G Foods Inc manufactures, sells, and distributes a range of branded, shelf-stable, and frozen food and household products across the United States, Canada, and Puerto Rico. Its products include frozen and canned vegetables, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, and wine vinegar. The company's main brands include Crisco, Clabber Girl, Bear Creek, Polaner, Underwood, B&G, Grandma's, New York Style, B&M, Baker's Joy, Regina, TrueNorth, Static Guard, SugarTwin and Brer Rabbit. It operates in four reportable segments: i) Specialty, the majoriy revenue generating segment, ii) Meals, iii) Frozen & Vegetables, iv) Spices & Flavor Solutions.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.